Executive Summary

Prepared April, 2026

Overview

Nutra Pharma Corporation operates as a biotechnology company specializing in the acquisition, licensing, and commercialization of pharmaceutical products and technologies for the management of neurological disorders, autoimmune, infectious diseases and pain.

The company carries out basic drug discovery research and clinical development, and also seeks strategic licensing partnerships to reduce the risks associated with the drug development process.

Currently, Nutra Pharma offers several drug products for sale for the treatment of pain: Nyloxin® - the first over-the-counter (OTC) pain reliever clinically proven to treat moderate to severe (Stage 2) chronic pain, Nyloxin® Extra Strength - the only non-prescription pain reliever for severe (Stage 3) pain *Pet Pain-Away* - the first OTC product to treat pain in companion animals without side effects and *Equine Pain-Away* – a powerful topical pain-reliever for horses.

The Company is also developing proprietary therapeutic protein products primarily for the prevention and treatment of viral and neurological diseases, including Multiple Sclerosis (MS), Adrenomyeloneuropathy (AMN), Human Immunodeficiency Virus (HIV), and pain in humans. Nutra Pharma has completed pre-clinical and animal models for their MS and HIV applications and are preparing to move into pivotal Phase II trials. **Nutra Pharma's MS drug has been granted Orphan Status by the FDA for the treatment of Pediatric Multiple Sclerosis.**

The short-term goals of the Company are to actively market and distribute the Nyloxin®, *Pet Pain-Away* and *Equine Pain-Away* product lines to generate immediate revenues. Nyloxin is available through independent Medical Distributors, several independent pharmacies as well as online through www.Nyloxin.com, Walmart.com and Amazon Prime. Nutra Pharma intends to market these products directly to the consumers to drive sales over the next 12 months. This includes infomercials and an eventual rollout into the retail space. Additionally, the Company has been registering these products in over 20 International Markets and has engaged distributors in 3 countries. The initial rollout into India is expected in 4Q2026.

The mid-term goal of the Company is to launch expansions to the analgesic product line. These will include Nyloxin Military Strength (for the US Military) as well as a tablet version of the Nyloxin product which will represent the first new over the counter pain tablet in 20 years.

Additionally, the long-term goal of the Company is to continue in the clinical development of the Multiple Sclerosis (MS), ALS and HIV drug platform. Phase II trials are planned in both applications with the final goal to be an out-licensing of these drugs to large Pharma partners.

Lastly, we are working with the Defense Threat Reduction Agency (DTRA) on cost plus contract to investigate RPI-78M as a potential nerve agent countermeasure. The initial contract is $19.6M

Board of Directors

Michael Flax, DDS	**Chairman and Chief Executive Officer, Nutra Pharma** Dr. Flax was appointed as our Chairman, CFO and CEO on March 20,2024. He was previously President and Chief Executive Officer of Nutra Pharma Corp. from November 2001 through November 2002. He also served as a Director of Nutra Pharma Corp. from November 2001 through June 2005. Dr. Flax has served on the Board of Appeals for United Healthcare of Fort Lauderdale, Florida. He served as the Program Director for Graduate Endodontics for the Nova Southeastern College of Dental Medicine in Fort Lauderdale. Dr. Flax served as the CEO and Co-Founder of Solstice Benefits in Fort Lauderdale. He served as an Associate Professor of Endodontics for the Nova Southeastern College of Dental Medicine in Fort Lauderdale. He was self-employed in the practice of Endodontics in Coral Springs, Florida. Dr. Flax served as an Instructor for the Department of Endodontics at the University of Pennsylvania School of Medicine – Graduate Division in Philadelphia, Pennsylvania. Dr. Flax served as an Instructor for the Department of Endodontics at Temple University School of Dentistry in Philadelphia, Pennsylvania. Dr. Flax is a Diplomate of the American Board of Endodontics, a member of the American Association of Endodontics, and a Fellow of the American College of Dentists. Dr. Michael Flax holds a certificate from the University of Pennsylvania School of Dental Medicine in Endodontics, 1986, a D.D.S. from Georgetown University Dental School, 1981, an M.S. in chemistry from St. John's University, 1977, and a B.A. major in chemistry, minor in engineering from Miami University in Oxford, Ohio. He is licensed to practice dentistry in the states of Florida, Maryland, New York, Pennsylvania, and the District of Columbia.
Stewart Lonky, MD	**Director - Audit & Compensation Committees** Dr. Lonky is board certified in internal medicine, pulmonary and critical care medicine. As a National Institutes of Health post-doctoral fellow and faculty member at the University of California, San Diego, he spearheaded a research team studying the cellular and biochemical mechanisms of lung injury. He has published over a dozen articles in the peer-reviewed literature in this field. His practice involves the evaluation and treatment of patients with toxic exposures as well as patients with lung disease, and he has co-authored the book Invisible Killers, The truth about environmental genocide. From 1990-2006 he served as Chief Medical Officer of a medical device company that developed diagnostic products for the early diagnosis of cervical and oral cancer. In that role, his duties included the direction of clinical research and the ultimate clearance of three new diagnostic devices by the U.S. Food and Drug Administration (FDA). Dr. Lonky has published numerous articles in the peer-reviewed literature in the area of cellular physiology and its relation to cervical and oral cancer detection. Since Early 2007 he has been a Board Member of Histologix, LLC, a company that is bringing innovative biopsy tools to the medical marketplace. Dr. Lonky is specifically involved with the regulatory clearances of these novel devices for use on various tissue surfaces. Dr. Lonky earned his B.S. degree at St. Lawrence University, his M.D. from the State University of New York, Downstate, and his M.B.A. from Pepperdine University.
Garry R. Pottruck CPA	**Director - Chairman, Audit & Compensation Committees** Garry R. Pottruck has been an independent tax and management consultant since 2011. Previously, from 2005 through 2010, he was a principal and manager in the accounting and consulting firm Argy, Wiltse & Robinson, PC ("Argy"), headquartered in McLean, Virginia. From July 1997 through October 2005 when the company was acquired by Argy, he was managing partner in the certified public accounting firm Friedberg & Pottruck, PA, located in Deerfield Beach, Florida, which specialized in providing accounting, tax and consulting services to physician practices. Mr. Pottruck held financial executive positions with several companies, both public and private, from 1984 through 1994, including more than three years as Chief Accounting Officer/Controller at Scopas Technology Company, Inc., a NASDAQ listed, development stage biotechnology research and development organization. Mr. Pottruck graduated with a B.S. in Accounting from the C.W. Post School of Professional Accountancy at Long Island University in 1979. He is currently a member of both the Florida and American Institutes of Certified Public Accounting, and is licensed in both Missouri and Florida.
Rik J. Deitsch	**Operations Manager, Nutra Pharma** Rik J. Deitsch has been the President, Chief Executive Officer and a Director of the Company since November 7, 2002 through March 18, 2024. Since Marhc of 2024, Mr. Deitsch has served as our Operations Manager. From February 1998 through November 2002, Mr. Deitsch served as the President of NDA Consulting Inc., a biotechnology research group that provided consulting services to the pharmaceutical industry. NDA Consulting specialized in the research of peptides derived from Cone Snail venom, Cobra venom and Gila Monster venom. Mr. Deitsch holds both a B.S. in Chemistry and an M.S. in Biochemistry from Florida Atlantic University and has conducted clinical and laboratory research in collaboration with scientists at Duke University Medical Center and the Cleveland Clinic. Mr. Deitsch is the author of two books and is an adjunct professor, teaching several courses for Florida Atlantic University's College of Business and Continuing Education Department.

Nyloxin®, *Pet Pain-Away* and *Equine Pain-Away*

Nyloxin® and Nyloxin® Extra Strength are Safe, Non-Narcotic, and Non-Addictive Pain Relievers Clinically Proven to Treat Moderate to Severe Chronic Pain While Not Impairing Cognitive Function.

These drugs offer several benefits as pain relievers and anti-inflammatory agents. With increasing concern about consumers using opioid and acetaminophen-based pain relievers, the Nyloxin brands offer an alternative that does not rely on opiates or non-steroidal anti-inflammatory drugs, otherwise known as NSAIDs, for their pain relieving effects. These drugs have a well-defined safety profile. Since the early 1930s, the active pharmaceutical ingredient (API), Asian cobra venom, has been studied in more than 46 human clinical studies. The data from these studies provide clinical evidence that cobra venom provides an effective treatment for pain with few side effects.

In 2012, Nutra Pharma launched Nyloxin for the treatment of moderate to severe (Stage 2) chronic pain and Nyloxin Extra Strength for the treatment of severe (Stage 3) pain.

Benefits of Nyloxin Include:

All Natural ♦ Non-Addictive ♦ Non-Narcotic ♦ Non-Opiate ♦ Long Lasting

Domestically, Nutra Pharma has been distributing the Nyloxin products through the website www.Nyloxin.com. As well as through Amazon Prime and Walmart.com. Nyloxin is sold in approximately fifty independent pharmacies and physician offices. Nutra Pharma has also been working continuously over the last year to register Nyloxin in countries all over the world. To that end, Nutra Pharma has announced distribution plans in: Canada, China and India. Nutra Pharma is currently working with large retailers with the expectation to be in at least 2,300 stores by the end of 2025.

Nutra Pharma has been working with Veteran groups to introduce Nyloxin as an opiate alternative. To date, the company has gotten approximately 1,000 Veterans off of their opiate drugs.

Pet Pain-Away™ was launched in December of 2014 and represents the very first OTC pain reliever for the companion animal market without substantial side effects. *Pet Pain-Away* is a great-tasting oral gel that provides pain relief and anti-inflammatory action for dogs and cats.

Benefits of *Pet Pain-Away* Include:

- All-Natural; Non-Addictive; Non-Opiate; NSAID-Free
- Hypoallergenic Chicken flavor that cats and dogs LOVE!

Pet Pain-Away is currently being sold online through Walmart and Amazon.

Equine Pain-Away was launched in October of 2019. It is currently being sold online through Amazon.

Nutra Pharma has formulated several product line extensions for launch in the near future. These include:

- *Nyloxin Military Strength*: pain relievers for the US military This formulation is twice the strength of Nyloxin Extra Strength.
- *Nyloxin Tablets*: a version of Nyloxin in a tablet that would represent the first new solid dose analgesic in almost 20 years.
- *Pet Pain-Away* chewable tablets for launch in the pet retail market.
- *Luxury Feet:* A pain reliever for women's feet to be sold in shoe stores and department stores

Private Labels: Nutra Pharma currently private labels their products as Ultimate Physician Pain Block for Dr. Mitch Ghen and Ease Therapeutics.

Drug Discovery

Nutra Pharma is developing proprietary therapeutic protein products for the billion-dollar biologics market. The Company has two leading drug candidates: RPI-MN and RPI-78M.

RPI-MN

RPI-MN inhibits the entry of several viruses that are known to cause severe neurological damage in such diseases as encephalitis and Human Immunodeficiency Virus (HIV). It is being developed first for the treatment of HIV.

RPI-78M

RPI-78M is being developed for the treatment of Multiple Sclerosis (MS) and Adrenomyeloneuropathy (AMN). Other neurological and autoimmune disorders that may be served by RPI-78M include Myasthenia Gravis (MG), Rheumatoid Arthritis (RA) and Amyotrophic Lateral Sclerosis (ALS).

RPI-78M and RPI-MN contain anticholinergic peptides that recognize the same receptors as nicotine (acetylcholine receptors) but have the opposite effect. In a specific chemical process unique to Nutra Pharma, the drugs are created through a process of chemical modification.

In September 2015 RPI-78M was ***granted Orphan Status by the FDA for the treatment of pediatric Multiple Sclerosis.*** This allows for much shorter timelines to drug approval, waiver of FDA fees (around $2.5M), rolling review and fast-track approval. Orphan status also allows for potential grant money and other funding opportunities through the clinical process.

RPI-MN and RPI-78M possess several desirable properties as drugs:

- They lack measurable toxicity but are still capable of attaching to and affecting the target site on the nerve cells. This means that patients cannot overdose.
- They display no serious adverse side effects following years of investigations in humans and animals.
- They are extremely stable and resistant to heat, which gives the drugs a long shelf life. The drugs' stability has been determined to be over 4 years at room temperature. This is extremely unusual for a biologic drug.
- RPI-78M may be administered orally -- a first for a biologic MS drug. This will present MS patients with additional quality of life benefits by eliminating the requirement for routine injections.
- They are easy to administer.

Benefits of Nutra Pharma's HIV/AIDs Treatment

RPI-MN	Fuzeon by Roche/Trimeris
Mutations are not Created	Mutations are Created
Relatively Inexpensive	Very Expensive – Twice Current Therapies
No Significant Adverse Side Effects	Adverse Side Effects Present – Some Severe
Long Shelf Life	Limited Shelf Life
Patient Does Not Develop Resistance	Patient Develops Immune Resistance
Easy to Manufacture	Difficult Manufacturing Leads to Limited Use

Benefits of (MS) Treatment

RPI-78M	Competitive Drugs
Disease Progress Stops	Disease Progression Only Slows
Patient Condition Improves	No Claims Against Patient Improvement
No Significant Adverse Side Effects	Adverse Side Effects Present – Some Severe
Long Shelf Life	Limited Shelf Life
Resistant to Heat	Requires Refrigeration
Patient Does Not Develop Resistance	Patient Develops Immune Resistance
Improves Quality of Life	No Evidence for Quality of Life Improvement

Research Pipeline

Nutra Pharma's research and development pipeline consists of several novel therapies in various stages of development to prevent and/or treat Multiple Sclerosis (MS), Human Immunodeficiency Virus (HIV), Adrenomyeloneuropathy (AMN), Herpes, Rheumatoid Arthritis (RA) and Pain.



RPI-78M



RPI-MN



RPI-78



Nutra Pharma Assets

The Company believes that current and near-term sales will provide funding for growth and the rollout of the extension lines over the next 12 months. As product sales increase and the cash reserves can support it, the Company will re-engage in the clinical trials to eventually license their Multiple Sclerosis drug and their HIV drug. The Company's platform also includes: Rheumatoid Arthritis, Osteoarthritis, Adrenomyeloneuropathy (AMN), Myasthenia Gravis (MG), Amyotrophic Lateral Sclerosis (ALS) and intractable Pain. Over time, all of these therapies can be proven and licensed to provide ongoing revenue streams and stability.

The current assets of the Company include product and component inventories and intellectual property (patents and trademarks). Nutra Pharma currently has Nyloxin inventory worth approximately $1M at retail. The Company currently has sixteen patents. Thirteen of these patents have been approved and two are pending. Three of these patents represent the bulk of our licensable drugs:

U.S. Patent No. 7,902,152, Use of cobratoxin as an analgesic was granted in March 2011 with 16 claims.

U.S. Patent No. 7,758,894, Modified elapid venoms as stimulators of the immune reaction was granted in July, 2010 with 14 claims.

U.S. Patent No. 8,034,777, Modified Anticholinergic Neurotoxins as Modulators of the Autoimmune Reaction was granted in October, 2011 with 7 claims.

We have an additional four patents in process to expand protections for our MS therapy, our ALS therapy as well as our nerve agent countermeasure project.

Nutra Pharma also owns trademarks for: Cobroxin®, Cobroxin for Chronic Pain®, Nyloxin® and Nyloxin Chronic Pain Relief®.

Nutra Pharma was granted Orphan Designation for the treatment of pediatric Multiple Sclerosis by the US-FDA for RPI-78M. This will allow for much faster, less expensive trials to get RPI-78M through the regulatory process.

Lastly, Nutra Pharma will continue to work with DTRA on their contract to utilize RPI-78M as a Nerve Agent Counter-Measure with the eventual goal of licensing and sales through the US Military.



Model of Alpha-Cobratoxin

For more information, please visit:

www.NutraPharma.com

Stock Symbol: NPHC

For more information, please visit: www.Nyloxin.com

For more information, please visit: www.PetPainAway.com

For more information, please visit: www.EquinePainAway.com

CONTACT:
Rik J Deitsch
Operations Manager
Office: 954-509-0911 x101
Fax: 877-895-5647
Rik.Deitsch@nutrapharma.com